Reducing the risk of perinatal HIV-1 transmission with zidovudine: results and implications of AIDS Clinical Trials Group protocol 076

L M Mofenson

doi:10.1111/j.1651-2227.1997.tb18328.x

Reducing the risk of perinatal HIV-1 transmission with zidovudine: results and implications of AIDS Clinical Trials Group protocol 076

Acta Paediatr Suppl. 1997 Jun:421:89-96. doi: 10.1111/j.1651-2227.1997.tb18328.x.

Author

L M Mofenson¹

Affiliation

¹ Pediatric, Adolescent & Maternal AIDS Branch, Center for Research for Mothers and Children, National Institute of Child Health & Human Development, National Institutes of Health, Rockville, MD 20852, USA.

PMID: 9240866
DOI: 10.1111/j.1651-2227.1997.tb18328.x

Abstract

This paper reviews the rationale for the AIDS Clinical Trials Group (ACTG) protocol 076 design, the study results and the implications of these results, including discussion of the US Public Health Service Task Force recommendations on the use of zidovudine to reduce perinatal transmission and for prenatal human immunodeficiency virus (HIV) counseling and testing.

Publication types

Review

MeSH terms

AIDS Serodiagnosis
Adult
Anti-HIV Agents / administration & dosage
Anti-HIV Agents / therapeutic use*
CD4 Lymphocyte Count
Counseling
Female
Gestational Age
HIV Infections / prevention & control*
HIV Infections / transmission*
HIV-1
Humans
Infant, Newborn
Infectious Disease Transmission, Vertical / prevention & control*
Mandatory Testing
Practice Guidelines as Topic
Pregnancy
Pregnancy Complications, Infectious / drug therapy
Pregnancy Complications, Infectious / prevention & control*
Randomized Controlled Trials as Topic
Research Design
Zidovudine / administration & dosage
Zidovudine / therapeutic use*

Substances

Anti-HIV Agents
Zidovudine